Bifeprunox

Bifeprunox

Bifeprunox

Experimental dopamine D2 receptor partial agonist researched as an antipsychotic agent

Bifeprunox (INN) (code name DU-127,090) is an atypical antipsychotic which, similarly to aripiprazole, combines minimal D2 receptor agonism with serotonin receptor agonism.[1] It was under development for the treatment of schizophrenia, psychosis and Parkinson's disease.[2]

Quick Facts Clinical data, ATC code ...

In a multi-center, placebo-controlled study, 20 mg of bifeprunox was found to be significantly more effective than placebo at reducing symptoms of schizophrenia, with a low incidence of side effects.[3] An NDA for Bifeprunox was filed with the U.S. Food and Drug Administration in January 2007. The FDA rejected the application in August 2007.[4] In June 2009, Solvay and Wyeth decided to cease development because "efficacy data did not support pursuing the existing development strategy of stabilisation of non-acute patients with schizophrenia."[5]

Pharmacodynamics

Bifeprunox is an atypical antipsychotic that is a partial D2 agonist.

See also

References

  1. [1]
    Cuisiat S, Bourdiol N, Lacharme V, Newman-Tancredi A, Colpaert F, Vacher B (2007). "Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities". J. Med. Chem. 50 (4): 865–76. doi:10.1021/jm061180b. PMID 17300168.
  2. [2]
    "Bifeprunox". go.drugbank.com. Retrieved 2023-11-16.
  3. [3]
    Casey DE, Sands EE, Heisterberg J, Yang HM (October 2008). "Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study". Psychopharmacology. 200 (3): 317–31. doi:10.1007/s00213-008-1207-7. PMID 18597078. S2CID 23291727.
  4. [4]
    Wyeth and Solvay say FDA rejects application for antipsychotic drug bifeprunox. Thomson Financial, August 10, 2007.
  5. [5]
    Pipeline update - following an interim analysis the studies with bifeprunox for the treatment of schizophrenia is discontinued Archived 2011-07-14 at the Wayback Machine Lundbeck Press Release.
Share this article:

This article uses material from the Wikipedia article Bifeprunox, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.